"6) What is the evidence of efficacy in NAFLD patients? This is the first we are hearing if this."

A search of my DD file came up with this

NASH (nonalcoholic steatohepatitis)

https://en.wikipedia.org/wiki/Non-alcoholic_fatty_liver_disease

https://www.investors.com/news/technology/nash-liver-disease-treatment-biotech-companies-billions-sales/

https://www.nature.com/articles/s41598-018-35653-4

https://www.cnbc.com/2018/12/21/the-35-billion-race-for-a-cure-for-a-liver-disease-that-affects-millions.html
"Industry experts estimate the global market for these new drugs is $35 billion."

Nlrp3 and the inflamasome activation (Parkinsons, Alzheimers, gout)

"NLRP3 has also been linked via preclinical data with nearly two dozen other conditions — including atherosclerosis, Alzheimer disease, gout, Parkinson disease, rheumatoid arthritis and non-alcoholic steatohepatitis (NASH).  

“All the big pharma companies want to block this target. It ticks all the boxes,” says O’Neill.""

https://www.nature.com/articles/d41573-019-00086-9

Apabetalone down-regulates NLRP3.